98%
921
2 minutes
20
Background: WHO, as requested by its member states, launched the Expanded Programme on Immunization (EPI) in 1974 to make life-saving vaccines available to all globally. To mark the 50-year anniversary of EPI, we sought to quantify the public health impact of vaccination globally since the programme's inception.
Methods: In this modelling study, we used a suite of mathematical and statistical models to estimate the global and regional public health impact of 50 years of vaccination against 14 pathogens in EPI. For the modelled pathogens, we considered coverage of all routine and supplementary vaccines delivered since 1974 and estimated the mortality and morbidity averted for each age cohort relative to a hypothetical scenario of no historical vaccination. We then used these modelled outcomes to estimate the contribution of vaccination to globally declining infant and child mortality rates over this period.
Findings: Since 1974, vaccination has averted 154 million deaths, including 146 million among children younger than 5 years of whom 101 million were infants younger than 1 year. For every death averted, 66 years of full health were gained on average, translating to 10·2 billion years of full health gained. We estimate that vaccination has accounted for 40% of the observed decline in global infant mortality, 52% in the African region. In 2024, a child younger than 10 years is 40% more likely to survive to their next birthday relative to a hypothetical scenario of no historical vaccination. Increased survival probability is observed even well into late adulthood.
Interpretation: Since 1974 substantial gains in childhood survival have occurred in every global region. We estimate that EPI has provided the single greatest contribution to improved infant survival over the past 50 years. In the context of strengthening primary health care, our results show that equitable universal access to immunisation remains crucial to sustain health gains and continue to save future lives from preventable infectious mortality.
Funding: WHO.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11140691 | PMC |
http://dx.doi.org/10.1016/S0140-6736(24)00850-X | DOI Listing |
Pharmacoecon Open
September 2025
Department of Pharmacy, The Second Affiliated Hospital of Army Medical University, No.83 Xinqiao Central Street, Shapingba District, Chongqing, 400037, China.
Objective: Two vaccines against herpes zoster (HZ) are currently authorized for use in China: the adjuvanted recombinant zoster vaccine (RZV) and live-attenuated Zoster Vaccine Live (ZVL). The significant disparities in prices and efficacy between the two vaccines necessitate an evaluation of their relative value in order to make an informed choice. This study aimed to evaluate the comparative cost effectiveness of RZV, ZVL, and no vaccination for older adults at different ages from the societal perspective.
View Article and Find Full Text PDFAfr J Prim Health Care Fam Med
August 2025
Department of Preventative Health Sciences, Faculty of Health, Natural Resources and Applied Sciences, Namibia University of Science and Technology (NUST), Windhoek.
Background: Cervical cancer remains a pressing public health concern in Namibia, with significant barriers to prevention, particularly in rural areas.
Aim: This study explored health system's challenges and their impact on cervical cancer prevention efforts.
Setting: This study was conducted in the Ohangwena and Kavango West regions of Namibia.
PLoS One
September 2025
Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China.
Background: Head and neck cancer (HNC) is a significant global health concern with rising incidence and mortality in certain regions. This study aimed to evaluate the global burden and temporal trends of HNC from 1990 to 2021 and to project its future burden through 2030.
Methods: Data were obtained from the Global Burden of Disease (GBD) 2021 study.
Cell
August 2025
Department of Cardiac Surgery, Jiangsu Provincial Key Laboratory of Critical Care Medicine, Zhongda Hospital, Key Laboratory of Developmental Genes and Human Disease, State Key Laboratory of Digital Medical Engineering, School of Biological Science and Medical Engineering, School of Life Science and
Early organogenesis is a crucial stage in embryonic development, characterized by extensive cell fate specification to initiate organ formation but also by a high susceptibility to developmental defects. Here, we profiled 285 serial sections from six E7.5-E8.
View Article and Find Full Text PDFJ Virol
September 2025
Division of Pediatric Infectious Disease, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Rift Valley fever virus (RVFV) causes mild to severe disease in livestock and humans. It was first identified in 1931 during an epizootic in Kenya and has spread across Africa and into the Middle East. Hematopoietic cells are one of the major targets of RVFV ; however, their contribution to RVFV pathogenesis remains poorly understood.
View Article and Find Full Text PDF